The blood levels of several immune-related proteins are significantly altered in people with ANCA-associated vasculitis (AAV) up to five years before they develop symptoms when compared with matched healthy people, a study showed. Changes in these protein levels were found to be involved in inflammatory and metabolic pathways, and…
Rituximab is superior to cyclophosphamide at inducing disease remission after six months in people with granulomatosis with polyangiitis (GPA) — a type of ANCA-associated vasculitis (AAV) — according to a study in France. Similar findings were found for subgroups of GPA patients, such as those newly diagnosed with the disease…
Up to six months of treatment with rituximab led to disease remission in about two-thirds of Japanese patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), a study found. Further, people in Japan with these two types of ANCA-associated vasculitis (AAV) who were given rituximab as a…
Over the past year, ANCA Vasculitis News has brought you coverage of the latest developments in research related to ANCA-associated vasculitis (AAV). We look forward to continuing to bring you news about advances in research and treatment in the new year. Here we have compiled a list of the top…
Adding a low dose of cyclophosphamide to rituximab for remission induction was safe and more effective at preventing relapses in the first two years in people with severe ANCA-associated vasculitis (AAV) than rituximab alone, a new study shows. No significant benefit was observed in the combination treatment after five years.
Blood levels of the soluble forms of CD28 and TIM-3 — two receptor proteins involved in the regulation of immune responses — are significantly associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) activity, a study showed. The levels of these so-called immune checkpoint molecules were increased in people with active AAV…
Hepatitis E infection can be effectively managed in people with ANCA-associated vasculitis (AAV) by pausing immunosuppressive therapy, though patients may experience AAV flares during this pause, a new study shows. “Despite potent immunosuppression before infection, all patients cleared the virus after cessation of the immunosuppressant without additional anti-viral therapy.
A 13-year-old girl developed ANCA-associated vasculitis (AAV) with major involvement of the central nervous system after COVID-19, a case study reports. “To our knowledge, this is the first reported pediatric case of ANCA-associated vasculitis with predominant central nervous system involvement after COVID-19 infection,” the researchers wrote. The girl had…
A 25-year-old man was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) after going to an outpatient clinic with joint pain and numbness in the hands and legs, according to a case study. He received treatment with corticosteroids and immunosuppressants, which stopped the EGPA progression and eased peripheral…
The CoronaVac COVID-19 vaccine has an excellent safety profile, but generates only a moderate immune response in people with ANCA-associated vasculitis (AAV), a clinical trial analysis found. Although the levels of vaccine-induced antibodies against SARS-CoV-2, the virus that causes COVID-19, declined over six months, a booster shot was shown…
Get regular updates to your inbox.